Glenmark Pharmaceuticals soars on reporting 21% rise in Q3 consolidated net profit
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Glenmark Pharmaceuticals is currently trading at Rs. 415.00, up by 15.15 points or 3.79% from its previous closing of Rs. 399.85 on the BSE.
The scrip opened at Rs. 410.00 and has touched a high and low of Rs. 422.35 and Rs. 405.20 respectively. So far 74155 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 498.40 on 11-Feb-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 422.35 and Rs. 385.85 respectively. The current market cap of the company is Rs. 11697.28 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 33.93% and 19.42% respectively.
Glenmark Pharmaceuticals has reported results for third quarter ended December 31, 2022 (Q3FY23).
The company has reported fall of 21.52% in its net profit at Rs 430.50 crore for Q3FY23 as compared to Rs 548.52 crore for the same quarter in the previous year. However, total income of the company marginally increased by 0.06% at Rs 2251.20 crore for the quarter under review as compared Rs 2249.80 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported rise of 21.28% in its net profit at Rs 290.76 crore for Q3FY23 as compared to Rs 239.75 crore for the same quarter in the previous year. Total income of the company increased by 11.07% to Rs 3540.27 crore for the quarter under review as compared to Rs 3187.31 crore for the same quarter in the previous year.
